Previous close | 38.00 |
Open | 38.50 |
Bid | 37.90 |
Ask | 41.45 |
Strike | 330.00 |
Expiry date | 2025-01-17 |
Day's range | 38.50 - 38.50 |
Contract range | N/A |
Volume | |
Open interest | 9 |
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.